BC
CORT icon

Bayforest Capital’s Corcept Therapeutics CORT Stock Holding History

Bayforest Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-233
Closed -$9.39K – 998
2026
Q1 		$9.39K Sell
233
-4,567
-95% -$171K 0.01% 797
2025
Q4 		$167K Buy
+4,800
New +$377K 0.12% 335
2025
Q2 		– Sell
-7,098
Closed -$811K – 769
2025
Q1 		$811K Buy
7,098
+5,739
+422% +$349K 0.35% 62
2024
Q4 		$68.5K Buy
+1,359
New +$71.2K 0.09% 405

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayforest Capital's CORT Position: Q2 2026 in Review

Bayforest Capital sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 233 shares — an estimated $9.39K sold.

Bayforest Capital first reported a position in CORT in Q4 2024 and held it in 4 quarters. The position peaked at $811K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Bayforest Capital reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bayforest Capital sold 233 Corcept Therapeutics shares in Q2 2026, an estimated $9.39K.
  • Bayforest Capital first reported a position in Corcept Therapeutics in Q4 2024 and held it in 4 quarters.
  • Bayforest Capital's Corcept Therapeutics position peaked at $811K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.